Segment, Geographical and Other Revenue Information (Tables)

6 Months Ended

Jun. 30, 2019

The following table provides financial information by our reportable business segments along with a reconciliation to consolidated loss before income taxes (in thousands):



	Three months ended June 30, 2019								Three months ended June 30, 2018
	Performance Enzymes		Novel Biotherapeutics			Total			Performance Enzymes		Novel Biotherapeutics			Total
Revenues:
Product revenue	$	6,249	$	—		$	6,249		$	3,723	$	—		$	3,723
Research and development revenue	4,340		1,730			6,070			7,442		2,373			9,815
Total revenues	10,589		1,730			12,319			11,165		2,373			13,538
Costs and operating expenses:
Cost of product revenue	2,772		—			2,772			2,611		—			2,611
Research and development⁽¹⁾	5,134		2,856			7,990			4,724		2,442			7,166
Selling, general and administrative	2,362		561			2,923			1,729		304			2,033
Total segment costs and operating expenses	10,268		3,417			13,685			9,064		2,746			11,810
Income (loss) from operations	$	321	$	(1,687	)	$	(1,366	)	$	2,101	$	(373	)	$	1,728
Corporate costs ⁽²⁾						(4,698		)						(5,209		)
Depreciation and amortization						(427		)						(265		)
Loss before income taxes						$	(6,491	)						$	(3,746	)

⁽¹⁾Research and development expenses exclude depreciation.

⁽²⁾Corporate costs include unallocated selling, general and administrative expense, interest income, and other income and expenses.



	Six months ended June 30, 2019									Six months ended June 30, 2018
	Performance Enzymes			Novel Biotherapeutics			Total			Performance Enzymes		Novel Biotherapeutics		Total
Revenues:
Product revenue	$	14,236		$	—		$	14,236		$	9,886	$	—	$	9,886
Research and development revenue	6,440			7,225			13,665			12,008		5,686		17,694
Total revenues	20,676			7,225			27,901			21,894		5,686		27,580
Costs and operating expenses:
Cost of product revenue	7,163			—			7,163			6,436		—		6,436
Research and development⁽¹⁾	9,576			6,172			15,748			9,790		4,374		14,164
Selling, general and administrative	4,463			1,078			5,541			3,825		450		4,275
Total segment costs and operating expenses	21,202			7,250			28,452			20,051		4,824		24,875
Income (loss) from operations	$	(526	)	$	(25	)	$	(551	)	$	1,843	$	862	$	2,705
Corporate costs⁽²⁾							(10,271		)					(10,644		)
Depreciation and amortization							(802		)					(503		)
Loss before income taxes							$	(11,624	)					$	(8,442	)

⁽¹⁾Research and development expenses exclude depreciation.

⁽²⁾Corporate costs include unallocated selling, general and administrative expense, interest income, and other income and expenses.

The following table provides stock-based compensation expense included in income (loss) from operations by segment (in thousands):



	Three months ended June 30, 2019						Three months ended June 30, 2018
	Performance Enzymes		Novel Biotherapeutics		Total		Performance Enzymes		Novel Biotherapeutics		Total
Stock-based compensation	$	601	$	197	$	798	$	768	$	83	$	851



	Six months ended June 30, 2019						Six months ended June 30, 2018
	Performance Enzymes		Novel Biotherapeutics		Total		Performance Enzymes		Novel Biotherapeutics		Total
Stock-based compensation	$	1,237	$	338	$	1,575	$	1,326	$	146	$	1,472

Schedule of customers that contributed 10% or more of total accounts receivable

Customers that each contributed 10% or more of our total revenues were as follows:



	Percentage of Total Revenues for the
	Three Months Ended June 30,		Six Months Ended June 30,
	2019	2018	2019	2018
Customer A	35%	27%	38%	38%
Customer B	14%	18%	26%	21%
Customer C	*	34%	*	22%
Customer D	11%	*	*	*

Customers that each contributed 10% or more of our total accounts receivable had the following balances as of the periods presented:



	Percentage of Accounts Receivables as of
	June 30, 2019	December 31, 2018
Customer A	39%	37%
Customer B	*	17%
Customer D	11%	*
Customer E	15%	*
Customer F	*	16%
Customer G	*	11%

* Less than 10% of the period presented

Schedule of revenues by geographical area

Geographic revenues are identified by the location of the customer and consist of the following (in thousands):



	Three Months Ended June 30,				Six Months Ended June 30,
	2019		2018		2019		2018
Revenues
Americas	$	4,076	$	6,058	$	6,913	$	9,655
EMEA	4,741		3,808		12,466		8,800
APAC	3,502		3,672		8,522		9,125
Total revenues	$	12,319	$	13,538	$	27,901	$	27,580

Schedule of long-lived assets by geographical area

Identifiable long-lived assets by location and goodwill by reporting unit were as follows:



Long-lived assets:	June 30, 2019		December 31, 2018
United States	$	30,936	$	4,759

Schedule of intangible assets and goodwill



	As of June 30, 2019 and December 31, 2018
	Performance Enzymes		Novel Biotherapeutics		Total
Goodwill	$	2,463	$	778	$	3,241